Luye Pharma Group Ltd (2186):製薬・医療:M&Aディール及び事業提携情報

◆英語タイトル:Luye Pharma Group Ltd (2186) - Pharmaceuticals & Healthcare - Deals and Alliances Profile
◆商品コード:DATA904C8100
◆発行会社(調査会社):GlobalData
◆発行日:2018年10月
◆ページ数:44
◆レポート言語:英語
◆レポート形式:PDF
◆納品方法:Eメール
◆対象地域:中国
◆産業分野:製薬・医療
◆販売価格オプション(消費税別)
Single User(1名様閲覧用)USD250 ⇒換算¥37,000見積依頼/購入/質問フォーム
Site License(同一事業所内共有可)USD500 ⇒換算¥74,000見積依頼/購入/質問フォーム
Enterprisewide License(複数事業所内共有可)USD750 ⇒換算¥111,000見積依頼/購入/質問フォーム
販売価格オプションの説明はこちらでご利用ガイドはこちらでご確認いただけます。
※お支払金額は「換算金額(日本円)+消費税+配送料(Eメール納品は無料)」です。
※本体価格が¥30,000未満のレポートにつきましては、ハンドリングチャージ¥5,000が別途かかります。
※Eメールによる納品の場合、通常ご注文当日〜2日以内に納品致します。
※レポート納品後、納品日+5日以内に請求書を発行し、お客様宛に郵送しますので、請求書発行日より2ヶ月以内に振込をお願いします。
※為替レートは適宜修正・更新しております。リアルタイム更新ではありません。
※弊社H&Iグローバルリサーチ株式会社はGlobalData社の日本における正規販売代理店です。同社発行の企業調査レポートに関するお問い合わせは弊社までお願い致します。
GlobalData社の概要はこちらでご確認いただけます。



【レポートの概要】

Summary
Luye Pharma Group Ltd (Luye Pharma Group) is a drug company that manufactures, develops, discovers, and commercializes novel formulations, natural drugs, medicinal products, pharmaceutical products, and biotechnology products. The group’s products include paclitaxel liposome, lentinan, sodium glycididazole, arsenious acid, and xuezhikang, among others. It also provides amifostine, oxaliplatin, meloxicam, pioglitazone hydrochloride, reduced glutathione, and selegiline hydrochloride, among others. Luye Pharma Group’s products are used in therapeutic areas including endocrinology, oncology, cardiovascular, orthopedics, gastroenterology, hepatology, gynecology, and central nervous system, among others. The group offers its products through its distributors located across China. Luye Pharma Group is headquartered in Yantai, China.

Luye Pharma Group Ltd (2186) – Pharmaceuticals & Healthcare – Deals and Alliances Profile provides you comprehensive data and trend analysis of the company’s Mergers and Acquisitions (M&As), partnerships and financings. The report provides detailed information on Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnership transactions recorded by the company over a five year period. The report offers detailed comparative data on the number of deals and their value categorized into deal types, sub-sector and regions.

GlobalData derived the data presented in this report from proprietary in-house Pharma eTrack deals database, and primary and secondary research.

Scope

- Financial Deals – Analysis of the company’s financial deals including Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnerships.
- Deals by Year – Chart and table displaying information encompassing the number of deals and value reported by the company by year, for a five year period.
- Deals by Type – Chart and table depicting information including the number of deals and value reported by the company by type such as Mergers and Acquisitions, Equity/Debt Offering etc.
- Deals by Region – Chart and table presenting information on the number of deals and value reported by the company by region, which includes North America, Europe, Asia Pacific, the Middle East and Africa and South and Central America.
- Deals by Sub-sector – Chart and table showing information on the number of deals and value reported by the company, by sub-sector.
- Major Deals – Information on the company’s major financial deals. Each such deal has a brief summary, deal type, deal rationale; and deal financials and target Company’s (major public companies) key financial metrics and ratios.
- Business Description – A brief description of the company’s operations.
- Key Employees – A list of the key executives of the company.
- Important Locations and Subsidiaries – A list and contact details of key centers of operation and subsidiaries of the company.
- Key Competitors – A list of the key competitors of the company.
- Key Recent Developments – A brief on recent news about the company.

Reasons to Buy

Get detailed information on the company’s financial deals that enable you to understand the company’s expansion/divestiture and fund requirements
- The profile enables you to analyze the company’s financial deals by region, by year, by business segments and by type, for a five year period.

Understand the company’s business segments’ expansion / divestiture strategy
- The profile presents deals from the company’s core business segments’ perspective to help you understand its corporate strategy.

Access elaborate information on the company’s recent financial deals that enable you to understand the key deals which have shaped the company
- Detailed information on major recent deals includes a summary of each deal, deal type, deal rationale, deal financials and Target Company’s key financial metrics and ratios.

Equip yourself with detailed information about the company’s operations to identify potential customers and suppliers.
- The profile analyzes the company’s business structure, locations and subsidiaries, key executives and key competitors.

Stay up-to-date on the major developments affecting the company
- Recent developments concerning the company presented in the profile help you track important events.

Gain key insights into the company for academic or business research
- Key elements such as break up of deals into categories and information on detailed major deals are incorporated into the profile to assist your academic or business research needs.

Note*: Some sections may be missing if data is unavailable for the company.

【レポートの目次】

Table of Contents
Table of Contents 3
List of Tables 4
List of Figures 4
Luye Pharma Group Ltd, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 5
Luye Pharma Group Ltd, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 6
Luye Pharma Group Ltd, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 7
Luye Pharma Group Ltd, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 8
Luye Pharma Group Ltd, Medical Devices Deals, 2012 to YTD 2018 10
Luye Pharma Group Ltd, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 11
Luye Pharma Group Ltd, Pharmaceuticals & Healthcare, Deal Details 12
Asset Purchase 12
Shandong Luye Pharma Acquires LY01008 and LY06006 from Shandong Boan Biological Technology for USD67 Million 12
Private Equity 13
CDH Investments, CITIC Private Equity and New Horizon Acquires Majority Stake in Luye Pharma 13
Partnerships 14
Luye Pharma Enters into Partnership with Elpis Biopharma 14
Licensing Agreements 15
Luye Pharma and Luye Supply to Enter into Agreement with Bayer 15
Abpro Enters into Licensing Agreement with Luye Pharma 16
Hanmi Pharm Enters into Licensing Agreement with Luye Pharma for Poziotinib 17
Excel BioPharma Enters into Licensing Agreement with Luye Pharma 18
Luye Pharma Group Enters Into Licensing Agreement With Dong-A Pharma For DA-1229 19
Equity Offering 20
Exicure Raises Additional USD11.2 Million in Private Placement of Shares 20
Luye Pharma Completes IPO 21
Debt Offering 23
Luye Pharma Plans to Raise up to USD302.6 Million in Public Offering of Notes 23
Acquisition 24
Luye Group May Acquire Ethypharm from Astorg Partners 24
A-Bio Pharma To Acquire 10% Stake In PrIME Biologics From NuSep For US$4.8 Million 25
Luye Pharma Group Ltd – Key Competitors 26
Luye Pharma Group Ltd – Key Employees 27
Luye Pharma Group Ltd – Locations And Subsidiaries 28
Head Office 28
Other Locations & Subsidiaries 28
Recent Developments 31
Financial Announcements 31
Mar 26, 2018: Luye Pharma Group: Annual Results Announcement For The Year Ended 31 December 2017 31
Aug 28, 2017: Luye Pharma Group: Announcement Of Interim Results For The Six Months Ended 30 June 2017 36
Mar 29, 2017: Luye Pharma Group: Annual Results Announcement For The Year Ended 31 December 2016 41
Clinical Trials 42
Jun 19, 2018: Luye Pharma Bolsters Its Global Analgesics Portfolio with China Class 1.1 New Compound LY03012 to Start Phase I Clinical Trials 42
Other Significant Developments 43
May 27, 2017: Investors flock to exicure s IPO – Luye Pharma s strategy of investment in novel biopharmaceuticals receives optimistic outlook 43
Appendix 44
Methodology 44
About GlobalData 44
Contact Us 44
Disclaimer 44

List of Tables
Luye Pharma Group Ltd, Pharmaceuticals & Healthcare, Key Facts, 2017 2
Luye Pharma Group Ltd, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 5
Luye Pharma Group Ltd, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 6
Luye Pharma Group Ltd, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 7
Luye Pharma Group Ltd, Deals By Therapy Area, 2012 to YTD 2018 8
Luye Pharma Group Ltd, Medical Devices Deals, 2012 to YTD 2018 10
Luye Pharma Group Ltd, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 11
Shandong Luye Pharma Acquires LY01008 and LY06006 from Shandong Boan Biological Technology for USD67 Million 12
CDH Investments, CITIC Private Equity and New Horizon Acquires Majority Stake in Luye Pharma 13
Luye Pharma Enters into Partnership with Elpis Biopharma 14
Luye Pharma and Luye Supply to Enter into Agreement with Bayer 15
Abpro Enters into Licensing Agreement with Luye Pharma 16
Hanmi Pharm Enters into Licensing Agreement with Luye Pharma for Poziotinib 17
Excel BioPharma Enters into Licensing Agreement with Luye Pharma 18
Luye Pharma Group Enters Into Licensing Agreement With Dong-A Pharma For DA-1229 19
Exicure Raises Additional USD11.2 Million in Private Placement of Shares 20
Luye Pharma Completes IPO 21
Luye Pharma Plans to Raise up to USD302.6 Million in Public Offering of Notes 23
Luye Group May Acquire Ethypharm from Astorg Partners 24
A-Bio Pharma To Acquire 10% Stake In PrIME Biologics From NuSep For US$4.8 Million 25
Luye Pharma Group Ltd, Key Competitors 26
Luye Pharma Group Ltd, Key Employees 27
Luye Pharma Group Ltd, Other Locations 28
Luye Pharma Group Ltd, Subsidiaries 28

List of Figures
Luye Pharma Group Ltd, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 2
Luye Pharma Group Ltd, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 2
Luye Pharma Group Ltd, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 2
Luye Pharma Group Ltd, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 2
Luye Pharma Group Ltd, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 5
Luye Pharma Group Ltd, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 6
Luye Pharma Group Ltd, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 7
Luye Pharma Group Ltd, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 8
Luye Pharma Group Ltd, Medical Devices Deals, 2012 to YTD 2018 10

★海外企業調査レポート[Luye Pharma Group Ltd (2186):製薬・医療:M&Aディール及び事業提携情報]についてメールでお問い合わせはこちら

■おすすめ企業レポート■
  • TIS Inc (3626):企業の財務・戦略的SWOT分析
    TIS Inc (3626) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses and the po …
  • Goodrich Petroleum Corp (GDP):企業の財務・戦略的SWOT分析
    Goodrich Petroleum Corp (GDP) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weakne …
  • Kalvista Pharmaceuticals Inc (KALV):医療機器:M&Aディール及び事業提携情報
    Summary Kalvista Pharmaceuticals Inc (Kalvista), formerly Carbylan Therapeutics Inc, is a pharmaceutical company that discovers, develops and commercializes small molecule protease inhibitors. The company’s product candidates are inhibitors of plasma kallikrein, which is being developed for heredita …
  • Compagnie Generale des Etablissements Michelin:企業の戦略・SWOT・財務情報
    Compagnie Generale des Etablissements Michelin - Strategy, SWOT and Corporate Finance Report Summary Compagnie Generale des Etablissements Michelin - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, ope …
  • Sirius XM Holdings Inc.:企業の戦略・SWOT・財務情報
    Sirius XM Holdings Inc. - Strategy, SWOT and Corporate Finance Report Summary Sirius XM Holdings Inc. - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service off …
  • RWE AG:企業の発電所・SWOT分析2018
    RWE AG - Power Plants and SWOT Analysis, 2018 Update Summary The report contains a detailed description of the power generation company’s business operations, history, corporate strategy, and business structure. This report contains a detailed SWOT analysis, information on key employees (executives) …
  • Wacker Chemie AG (WCH):企業の財務・戦略的SWOT分析
    Wacker Chemie AG (WCH) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses an …
  • Regulus Therapeutics Inc (RGLS):製薬・医療:M&Aディール及び事業提携情報
    Summary Regulus Therapeutics Inc (Regulus Therapeutics) is a biopharmaceutical company that discovers and develops microRNA based therapeutics. The company provides single stranded oligonucleotides, which are chemically synthesized chains of nucleotides that are mirror images of specific target micr …
  • Bush Industries Inc:企業の戦略・SWOT・財務分析
    Bush Industries Inc - Strategy, SWOT and Corporate Finance Report Summary Bush Industries Inc - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings a …
  • Tradewinds Corporation Berhad:戦略・SWOT・企業財務分析
    Tradewinds Corporation Berhad - Strategy, SWOT and Corporate Finance Report Summary Tradewinds Corporation Berhad - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and …
  • Key Energy Services, Inc. (KEG)-石油・ガス分野:企業M&A・提携分析
    Summary Key Energy Services, Inc. (Key) is an onshore, rig-based well servicing contractor, which offers a range of rig services. Its service line includes rig-based and coiled tubing-based well maintenance and workover services, well completion and recompletion services, fluid management services, …
  • Hitachi Medical Systems America Inc-医療機器分野:企業M&A・提携分析
    Summary Hitachi Medical Systems America Inc (Hitachi Medical), a subsidiary of Hitachi Healthcare Manufacturing Ltd is a provider of diagnostic imaging equipment. The company offers MRI, CT, ultrasound, optical topography and x-ray equipment. Its services comprise construction assistance, rigging as …
  • The Walt Disney Company:企業の戦略・SWOT・財務分析
    The Walt Disney Company - Strategy, SWOT and Corporate Finance Report Summary The Walt Disney Company - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service off …
  • Petroleos de Venezuela SA:企業の戦略的SWOT分析
    Petroleos de Venezuela SA - Strategic SWOT Analysis Review provides a comprehensive insight into the company’s history, corporate strategy, business structure and operations. The report contains a detailed SWOT analysis, information on the company’s key employees, key competitors and major products …
  • Creganna Medical:企業の戦略的SWOT分析
    Creganna Medical - Strategic SWOT Analysis Review provides a comprehensive insight into the company’s history, corporate strategy, business structure and operations. The report contains a detailed SWOT analysis, information on the company’s key employees, key competitors and major products and servi …
  • Pressure Biosciences Inc:企業のM&A・事業提携・投資動向
    Pressure Biosciences Inc - Mergers & Acquisitions (M&A), Partnerships & Alliances and Investment Report Summary Marketline's Pressure Biosciences Inc Mergers & Acquisitions (M&A), Partnerships & Alliances and Investments report includes business description, detailed reports on mergers and acquisiti …
  • Chokwang Paint Co Ltd (004910):企業の財務・戦略的SWOT分析
    Chokwang Paint Co Ltd (004910) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weakn …
  • Regal Petroleum plc (RPT):企業の財務・戦略的SWOT分析
    Summary Regal Petroleum Plc (Regal), a subsidiary of Energees Investments Ltd, is an oil and gas company that conducts reviews on oil and gas projects. The company operates two gas and condensate fields such as Mekhediviska - Golotovschinska and Svyrydivske located in Dneipner-Donets basin in the no …
  • iKang Healthcare Group Inc:戦略・SWOT・企業財務分析
    iKang Healthcare Group Inc - Strategy, SWOT and Corporate Finance Report Summary iKang Healthcare Group Inc - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and servi …
  • Acorda Therapeutics Inc (ACOR):企業の財務・戦略的SWOT分析
    Acorda Therapeutics Inc (ACOR) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weakn …

◆H&Iグローバルリサーチ株式会社のお客様(例)◆